Shaohua M. Zhang

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First-Line Treatment of HER2+ MBC: A Multicenter Real-World Study.

Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First-Line Treatment of HER2+ MBC: A Multicenter Real-World Study.

Journal: Cancer medicine

Published: November 08, 2025

Dalpiciclib plus chidamide in HR + /HER2-advanced breast cancer after CDK4/6 inhibitor failure: a phase Ib trial.

Dalpiciclib plus chidamide in HR + /HER2-advanced breast cancer after CDK4/6 inhibitor failure: a phase Ib trial.

Journal: Nature communications

Published: August 29, 2025

Effect of Anticholinergic Drug Burden on Postoperative Delirium in Elderly Patients: A Nested Case-Control Study.

Effect of Anticholinergic Drug Burden on Postoperative Delirium in Elderly Patients: A Nested Case-Control Study.

Journal: CNS neuroscience & therapeutics

Published: August 13, 2025

Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04.

Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: June 21, 2025

Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2.

Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: June 02, 2025

Real-World Treatment Patterns and Survival Outcomes in Metastatic Triple Negative Breast Cancer: Immunotherapy- Versus Anti-Angiogenic Therapy-Combined-With-Chemotherapy.

Real-World Treatment Patterns and Survival Outcomes in Metastatic Triple Negative Breast Cancer: Immunotherapy- Versus Anti-Angiogenic Therapy-Combined-With-Chemotherapy.

Journal: Cancer medicine

Published: June 02, 2025

Effects of non-pharmacological interventions in patients with cancer-related cognitive impairment: A meta-analysis.

Effects of non-pharmacological interventions in patients with cancer-related cognitive impairment: A meta-analysis.

Journal: International journal of nursing studies

Published: May 31, 2025

Extracellular vesicles derived from senescent hepatocytes drive pan-cancer metastasis in aging.

Extracellular vesicles derived from senescent hepatocytes drive pan-cancer metastasis in aging.

Journal: Nature aging

Published: May 26, 2025

Anti-HER2 plus endocrine therapy versus anti-HER2 plus chemotherapy in hormone receptor-positive and HER2-positive metastatic breast cancer: a retrospective study.

Anti-HER2 plus endocrine therapy versus anti-HER2 plus chemotherapy in hormone receptor-positive and HER2-positive metastatic breast cancer: a retrospective study.

Journal: International journal of clinical oncology

Published: May 05, 2025

Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial.

Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 28, 2025

Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses.

Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: March 24, 2025

Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy.

Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy.

Journal: Scientific reports

Published: January 30, 2025

Showing 1-12 of 49

Last Updated: 09/26/2026